Trending Now

Nivesh.live

Invest Wisely, Grow Steadily

Menu
Search
Headline
10 reasons why gold is a good buy in 2025 – CNBC TV18
10 reasons why gold is a good buy in 2025 – CNBC TV18
Tata Motors shares up 5% but tariff troubles continue to linger – CNBC TV18
Tata Motors shares up 5% but tariff troubles continue to linger – CNBC TV18
Muthoot Finance shares fall over 8% in reaction to draft RBI norms, Kotak downgrade – CNBC TV18
Muthoot Finance shares fall over 8% in reaction to draft RBI norms, Kotak downgrade – CNBC TV18
National Pet Day 2025: A look at pet insurance coverage in India and what’s included – CNBC TV18
National Pet Day 2025: A look at pet insurance coverage in India and what’s included – CNBC TV18
Bharti Hexacom shares in focus after deal to sell 3,400 towers to Indus Towers halted – CNBC TV18
Bharti Hexacom shares in focus after deal to sell 3,400 towers to Indus Towers halted – CNBC TV18
Samvardhana Motherson aims for €50 million in cost savings with latest measures – CNBC TV18
Samvardhana Motherson aims for €50 million in cost savings with latest measures – CNBC TV18
Asian shares sink, with Japan’s Nikkei down 5.6% as China-US trade war escalates – CNBC TV18
Asian shares sink, with Japan’s Nikkei down 5.6% as China-US trade war escalates – CNBC TV18
GIFT Nifty surges nearly 500 points indicating a potential gap-up despite US sell-off – CNBC TV18
GIFT Nifty surges nearly 500 points indicating a potential gap-up despite US sell-off – CNBC TV18
Sensex Today | Stock Market LIVE Updates: Sensex, Nifty 50 likely to make a gap down start on Wednesday
Sensex Today | Stock Market LIVE Updates: Sensex, Nifty 50 likely to make a gap down start on Wednesday

Tag: Gland Pharma downgrade

Markets
Sarvesh Gautam

Goldman Sachs expects Gland Pharma shares to fall back to their IPO price – CNBC TV18

[ad_1] Brokerage firm Goldman Sachs has downgraded shares of Gland Pharma to “sell” from its earlier rating of “buy”. The brokerage has also cut its price target by 27% to ₹1,500 from ₹2,075 earlier. In fact, Goldman Sachs’ price target is exactly the IPO price of Gland Pharma when it made its street debut in […]

Back To Top
Translate »